Christine Parsons1, Salma I Patel1, Stephen Cha2, Win-Kuang Shen3, Santosh Desai3, Alanna M Chamberlain4, Sushil Allen Luis5, Maria I Aguilar6, Bart M Demaerschalk6, Farouk Mookadam3, Fadi Shamoun7. 1. Department of Medicine, Mayo Clinic, Scottsdale, AZ. 2. Department of Health Sciences Research, Mayo Clinic, Scottsdale, AZ. 3. Division of Cardiovascular Diseases, Mayo Clinic, Scottsdale, AZ. 4. Department of Health Sciences Research, Mayo Clinic, Rochester, MN. 5. Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN. 6. Department of Neurology, Mayo Clinic, Scottsdale, AZ. 7. Division of Cardiovascular Diseases, Mayo Clinic, Scottsdale, AZ. Electronic address: Shamoun.Fadi@mayo.edu.
Abstract
OBJECTIVE: To determine if the CHA2DS2-VASc score (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke or transient ischemic attack, vascular disease, age 65-74 years, sex category) predicts thromboembolism and death in patients without atrial fibrillation in a population with implantable cardiac monitoring devices. PATIENTS AND METHODS: A retrospective review utilizing the Rochester Epidemiology Project research infrastructure was conducted to evaluate the CHA2DS2-VASc tool as a predictor of mortality and ischemic stroke, transient ischemic attack, or systemic embolism in patients without atrial fibrillation. An implantable device was required in the inclusion criteria to discern the absence of atrial fibrillation. The study period was January 1, 2004, through March 7, 2016. RESULTS: The study population (N=1606) had a mean (SD) age of 69.8 (12.6) years and median follow-up of 4.8 years (range, 0-12 years; quartile 1, 2.6 years and quartile 3, 8.1 years). The number of thromboembolic and mortality events stratified by CHA2DS2-VASc score groupings of 0 to 2 (399 patients), 3 to 5 (756 patients), and 6 to 9 (451 patients) were 12 (3.0%), 109 (14.4%), and 123 (27.3%) and 22 (5.5%), 205 (27.1%), and 214 (47.4%), respectively. The CHA2DS2-VASc score predicted thromboembolism and death. The hazard ratios (HRs) for thromboembolic events for CHA2DS2-VASc scores 3 to 5 and 6 to 9 were 4.84 (95% CI, 2.66-8.80) and 10.53 (95% CI, 5.77-19.21) (reference group, scores 0-2). The HRs for death for the corresponding score categories were 4.45 (95% CI, 2.86-6.91) and 8.18 (95% CI, 5.23-12.78). The CHA2DS2-VASc score also predicted development of atrial fibrillation, for which the HRs for scores 3 to 5 and 6 to 9 were 1.51 (95% CI, 1.13-2.00) and 2.17 (95% CI, 1.60-2.95). CONCLUSION: The CHA2DS2-VASc tool predicts thromboembolic events and overall mortality in patients without atrial fibrillation who have implantable devices.
OBJECTIVE: To determine if the CHA2DS2-VASc score (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke or transient ischemic attack, vascular disease, age 65-74 years, sex category) predicts thromboembolism and death in patients without atrial fibrillation in a population with implantable cardiac monitoring devices. PATIENTS AND METHODS: A retrospective review utilizing the Rochester Epidemiology Project research infrastructure was conducted to evaluate the CHA2DS2-VASc tool as a predictor of mortality and ischemic stroke, transient ischemic attack, or systemic embolism in patients without atrial fibrillation. An implantable device was required in the inclusion criteria to discern the absence of atrial fibrillation. The study period was January 1, 2004, through March 7, 2016. RESULTS: The study population (N=1606) had a mean (SD) age of 69.8 (12.6) years and median follow-up of 4.8 years (range, 0-12 years; quartile 1, 2.6 years and quartile 3, 8.1 years). The number of thromboembolic and mortality events stratified by CHA2DS2-VASc score groupings of 0 to 2 (399 patients), 3 to 5 (756 patients), and 6 to 9 (451 patients) were 12 (3.0%), 109 (14.4%), and 123 (27.3%) and 22 (5.5%), 205 (27.1%), and 214 (47.4%), respectively. The CHA2DS2-VASc score predicted thromboembolism and death. The hazard ratios (HRs) for thromboembolic events for CHA2DS2-VASc scores 3 to 5 and 6 to 9 were 4.84 (95% CI, 2.66-8.80) and 10.53 (95% CI, 5.77-19.21) (reference group, scores 0-2). The HRs for death for the corresponding score categories were 4.45 (95% CI, 2.86-6.91) and 8.18 (95% CI, 5.23-12.78). The CHA2DS2-VASc score also predicted development of atrial fibrillation, for which the HRs for scores 3 to 5 and 6 to 9 were 1.51 (95% CI, 1.13-2.00) and 2.17 (95% CI, 1.60-2.95). CONCLUSION: The CHA2DS2-VASc tool predicts thromboembolic events and overall mortality in patients without atrial fibrillation who have implantable devices.
Authors: Line Melgaard; Anders Gorst-Rasmussen; Deidre A Lane; Lars Hvilsted Rasmussen; Torben Bjerregaard Larsen; Gregory Y H Lip Journal: JAMA Date: 2015-09-08 Impact factor: 56.272
Authors: Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy Journal: J Am Coll Cardiol Date: 2014-03-28 Impact factor: 24.094
Authors: Marcos Daccarett; Troy J Badger; Nazem Akoum; Nathan S Burgon; Christian Mahnkopf; Gaston Vergara; Eugene Kholmovski; Christopher J McGann; Dennis Parker; Johannes Brachmann; Rob S Macleod; Nassir F Marrouche Journal: J Am Coll Cardiol Date: 2011-02-15 Impact factor: 24.094
Authors: Wenjun Zhong; Hilal Maradit-Kremers; Jennifer L St Sauver; Barbara P Yawn; Jon O Ebbert; Véronique L Roger; Debra J Jacobson; Michaela E McGree; Scott M Brue; Walter A Rocca Journal: Mayo Clin Proc Date: 2013-06-19 Impact factor: 7.616
Authors: Karin M Henriksson; Bahman Farahmand; Saga Johansson; Signild Asberg; Andreas Terént; Nils Edvardsson Journal: Int J Cardiol Date: 2009-01-13 Impact factor: 4.164
Authors: Renate B Schnabel; Martin G Larson; Jennifer F Yamamoto; Sekar Kathiresan; Jian Rong; Daniel Levy; John F Keaney; Thomas J Wang; Ramachandran S Vasan; Emelia J Benjamin Journal: Am J Cardiol Date: 2009-05-04 Impact factor: 2.778
Authors: V Roldán; F Marín; S Manzano-Fernandez; H Fernández; P Gallego; M Valdés; V Vicente; G Y H Lip Journal: Thromb Haemost Date: 2013-03-21 Impact factor: 5.249
Authors: C Weimar; M Goertler; J Röther; E B Ringelstein; H Darius; D G Nabavi; In-Ha Kim; Jens Benemann; Hans-Christoph Diener Journal: J Neurol Neurosurg Psychiatry Date: 2008-06-27 Impact factor: 10.154